FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology. Disclosed are the following peptide immunogens: the first peptide immunogen used as a component of vaccine composition against COVID-19 characterized by the amino acid sequence CRLFRKSNLKPFERDISTEIYQAGS (SEQ ID NO: 1); the second peptide immunogen used as a component of vaccine composition against COVID-19 characterized by the amino acid sequence CKEIDRLNEVAKNLNESLIDLQELGKYEQYIK (SEQ ID NO: 2). Disclosed is vaccine composition against COVID-19 characterized by the fact that it contains peptide immunogens having amino acid sequences (SEQ ID NO: 1) and (SEQ ID NO: 2). These peptide immunogens are covalently linked in the form of conjugates with a carrier protein, which is a chimeric recombinant protein MBP-6xHis-N_nCoV-2019 including the N protein of the SARS Cov-2 coronavirus characterized by the amino acid sequence (SEQ ID NO: 3). The mixture of the above conjugates of peptide immunogens and a carrier protein is sorbed onto a pharmaceutically acceptable adjuvant.
EFFECT: peptide immunogens and vaccine compositions that carry minimum necessary antigenic determinants for the formation of a specific immune response in rabbits, weasels and hamsters and induce protective immunity against COVID-19.
5 cl, 4 tbl, 7 ex, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE IMMUNOGENS AND A VACCINE COMPOSITION AGAINST CORONAVIRUS INFECTION COVID-19 USING PEPTIDE IMMUNOGENS | 2020 |
|
RU2738081C1 |
| PEPTIDE IMMUNOGENS USED AS COMPONENTS OF VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743594C1 |
| VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743595C1 |
| ARTIFICIAL GENETIC CONSTRUCT FOR THE HETEROLOGOUS EXPRESSION OF THE S-PROTEIN RECEPTOR-BINDING DOMAIN IN A FUSED POLYPEPTIDE CHAIN WITH A NUCLEOCAPSID PROTEIN | 2022 |
|
RU2801597C1 |
| METHOD FOR TREATING PATIENTS WITH A NEW CORONAVIRUS INFECTION COVID-19 WITH HIGH-FLOW OXYGENATION | 2022 |
|
RU2787175C1 |
| ARTIFICIAL GENE CODING A BICISTRONIC STRUCTURE FORMED BY RECEPTOR-BINDING DOMAIN SEQUENCES OF THE GLYCOPROTEIN S OF THE SARS-COV-2 CORONAVIRUS, P2A-PEPTIDE AND GLYCOPROTEIN G VSV, RECOMBINANT PLASMID PSTEM-RVSV-STBL_RBD_SC2, PROVIDING EXPRESSION OF ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-STBL_RBD_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733831C1 |
| ARTIFICIAL GENE STBL_RBD_TRM_SC2, CODING A BICISTRONIC STRUCTURE FORMED BY THE SARS-COV-2 CORONAVIRUS GLYCOPROTEIN S RECEPTOR-BINDING DOMAIN SEQUENCES, TRANSMEMBRANE REGION, P2A-PEPTIDE AND GLYCOPROTEIN G VSV, RECOMBINANT PLASMID PSTEM-RVSV-STBL_RBD_TRM_SC2, PROVIDING EXPRESSION OF ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-STBL_RBD_TRM_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733832C1 |
| ARTIFICIAL ECTOS_SC2 GENE ENCODING AN ECTODOMAIN OF THE SARS-COV-2 CORONAVIRUS S GLYCOPROTEIN WITH A C-TERMINAL TRIMERIZATION DOMAIN, A RECOMBINANT PLASMID PSTEM-RVSV-ECTOS_SC2, WHICH PROVIDES EXPRESSION OF THE ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-ECTOS_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733834C1 |
| METHOD OF CREATING A LIVE VACCINE AGAINST COVID-19 BASED ON THE PROBIOTIC STRAIN ENTEROCOCCUS FAECIUM L3 AND A LIVE VACCINE ENTEROCOCCUS FAECIUM L3-PENTF-COVID-19 | 2020 |
|
RU2745626C1 |
| METHOD FOR CREATING RECOMBINANT ENTEROCOCCUS L3-SARSN1 STRAIN BASED ON BIOLOGICALLY ACTIVE ENTEROCOCCUS FAECIUM L3 STRAIN | 2022 |
|
RU2820058C1 |
